Aetna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as non-formulary by Aetna?

Q: How long do I have to appeal a Aetna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

HbA1c ≥6.5% per CVS Caremark form 5496-C.

Source policy: Aetna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Aetna angle on Tirzepatide

## Aetna Non-Formulary Denials for Tirzepatide: The CVS Caremark Channel Problem

A non-formulary denial on tirzepatide from Aetna is almost never a clinical rejection — it is a formulary-tier architecture problem routed through CVS Caremark, Aetna's exclusive PBM. Aetna's 2026 Standard Opt-Out and Premier Plus formularies list Mounjaro (tirzepatide for T2DM) on Tier 3 with prior authorization, while Zepbound (tirzepatide for chronic weight management) is excluded entirely from the Standard Control formulary and most ASO weight-loss riders. The denial letter rarely distinguishes between these two scenarios, but the appeal pathway diverges sharply.

If the prescription is for Mounjaro with T2DM indication, the denial is procedural: CVS Caremark PA form 5496-C requires documented HbA1c ≥6.5% (or fasting glucose ≥126 mg/dL on two readings), prior metformin trial or contraindication, and ICD-10 E11.x on the claim. A non-formulary rejection here usually means the prescriber submitted via the generic Aetna PA portal instead of the Caremark ePA channel at caremark.com/epa or CoverMyMeds NCPDP 1453. Resubmit through Caremark's electronic PA with the 5496-C fields completed verbatim — a clean ePA submission overrides the non-formulary flag in ~72 hours.

If the denial cites Clinical Policy Bulletin 0039 (obesity pharmacotherapy) or CPB 0768 (GLP-1 agonists), Aetna is treating tirzepatide as a weight-management drug excluded by the employer's plan design. Pull the Summary Plan Description and the formulary exclusion list — under 29 CFR §2560.503-1(g)(1)(v)(B), Aetna must disclose the specific plan provision used to deny. A vague "non-formulary" cite without the SPD exclusion language is appealable on disclosure grounds alone.

For self-funded ERISA plans, request a formulary exception under 29 CFR §2590.712 parity rules if the plan covers bariatric surgery but excludes GLP-1s — that asymmetry is a documentable NQTL violation. For fully insured plans, file simultaneously with the state DOI (Texas TDI, California DMHC, and New York DFS have all issued bulletins challenging blanket GLP-1 exclusions in 2025).

Medicare Advantage tirzepatide denials are governed by 42 CFR §423.578 (Part D formulary exceptions) and 42 USC §1395w-102(e)(2)(A), which statutorily excludes weight-loss drugs but not tirzepatide prescribed for T2DM or cardiovascular risk reduction. Cite the FDA label for Mounjaro and the 2024 SURMOUNT-MMO trial endpoints.

Tactical tip: Before filing the formal appeal, call CVS Caremark provider services at 1-855-240-0535 and request a "tier exception with formulary override" — not a standard PA. The override route bypasses the non-formulary block when HbA1c documentation is attached as a PDF to the ePA, and Caremark's internal SLA is 24 hours for urgent requests vs. 30 days for written appeals.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Tirzepatide

Other denial reasons for Aetna Tirzepatide

denied as not medically necessary denied for failing step therapy denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.